Navigation Links
GenSpera to Present at Rodman & Renshaw 16th Annual Global Investment Conference
Date:8/14/2014

SAN ANTONIO, Aug. 14, 2014 /PRNewswire/ -- GenSpera, Inc. (OTCQB: GNSZ), a leader in developing prodrug therapeutics for the treatment of cancer, announces it will be presenting at the Rodman & Renshaw 16th Annual Global Investment Conference. The conference will be held September 8-10, 2014 at the New York Palace Hotel in New York.

The conference is attended by public companies, institutional investors, sophisticated private investors and industry executives.

GenSpera will be presenting at 12:05 pm Tuesday, September 9th. The Company will discuss the significance of the recently announced HCC clinical trial update for G-202, its lead drug candidate, as well as provide a corporate overview. The company has released interim results from the Phase Ib and ongoing Phase II study in hepatocellular carcinoma (HCC) patients who had previously progressed on, or who were intolerant of sorafenib ( Nexavar®, a drug co-developed and co-marketed by Bayer and Onyx Pharmaceuticals, an Amgen subsidiary).  Impressively, 80% of patients treated with G-202 had stable disease (no tumor growth) at two months and 50% of patients exhibited stable disease at 4 months on study. In addition, imaging analysis demonstrated impressive blockade of tumor blood flow in the single patient evaluated by this method to date.

Hepatocellular carcinoma (HCC) is currently the sixth most common malignancy in the world and the third leading cause of cancer-related mortality worldwide.

Craig Dionne, PhD, GenSpera's CEO said of the pending conference," I am excited to share the recent data and results for G-202 and its efficacy and safety analyses on patients to date. G-202 has potential to treat multiple cancers including prostate cancer and glioblastoma but our primary focus is currently hepatocellular carcinoma (HCC). The liver cancer data we recently presented at APPLE and other scientific conferences was overwhelmingly embraced by our peers; now this conference creates an opportunity to explain the significance and the promise it holds to the investment community."

About the conference: http://www.rodm.com/

About GenSpera
GenSpera's technology platform combines a powerful, plant-derived cytotoxin (thapsigargin) with a prodrug delivery system that provides for the targeted release of drug candidates within a tumor. Unlike typical chemotherapeutic agents, thapsigargin results in cell death irrespective of the rate of cell division, which may provide an effective approach to kill both fast- and slow-growing cancers. GenSpera's lead drug candidate, G-202, is activated by the enzyme PSMA, which is found at high levels in the vasculature of liver and glioblastoma cancers and in the vasculature of almost all other solid tumors. G-202 is therefore expected to have potential efficacy in a wide variety of tumor types.

G-202 Phase II clinical trials are underway in both hepatocellular carcinoma and glioblastoma patients.

For more information, please visit the company's website: www.genspera.com or follow us on Twitter @GenSperaNews.

Company presentations are available at: http://www.genspera.com/

Watch the Corporate Video:
http://youtu.be/jULjEul-mBk

Cautionary Statement Regarding Forward Looking Information
This news release may contain forward-looking statements. Investors are cautioned that statements in this press release regarding potential applications of GenSpera's technologies constitute forward-looking statements that involve risks and uncertainties, including, without limitation, risks inherent in the development and commercialization of potential products, uncertainty of clinical trial results or regulatory approvals or clearances, need for future capital, dependence upon collaborators and maintenance of our intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements. Additional information on potential factors that could affect our results and other risks and uncertainties will be detailed from time to time in GenSpera's periodic reports filed with the Securities and Exchange Commission.

CONTACT:                  

Company:
Craig Dionne, PhD, CEO
GenSpera, Inc.  (210) 479-8112

Investors: 
Steve Gersten
Capital Markets Group
Steve@CapMarketsGroup.com
+1-813-926-8920

Media:
Dawn Van Zant
(800) 665 0411


'/>"/>
SOURCE GenSpera, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. GenSpera Presents G-202 HCC Clinical Trial Update at 5th Asia-Pacific Primary Liver Cancer Expert Meeting
2. Kareg Corporation Initiates Coverage on GenSpera with a Speculative Buy Recommendation
3. Aventura Client Presents Enhancing Emergency Department Documentation Efficiency at Optum Client Forum 2014
4. Lpath to Present at 34th Annual Canaccord Genuity Growth Conference
5. Genomic Health to Present at the Canaccord Genuity 34th Annual Growth Conference
6. Lexicon To Present At The 2014 Wedbush Life Sciences Management Access Conference
7. Omeros to Present at the Wedbush PacGrow 2014 Life Sciences Management Access Conference
8. Guardant Health to Present at the WedBush 2014 Life Sciences Management Access Conference
9. Mast Therapeutics To Present At The Canaccord Genuity 34th Annual Growth Conference On August 14th
10. STAAR Surgical To Present At Wedbush And Canaccord Investor Conferences
11. KemPharm, Inc. to Present at the Canaccord Genuity 34th Annual Growth Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... , Australie, le 24 février 2017 ITL Limited, ... santé diversifiée innovante, est ravie d,annoncer les excellents résultats ... la période précédente correspondante. Une présentation complète « Résultats et ... être consultée ici . Faits ... de 2,12 millions $ (Déc. 2015 : 1,04 million $ ; en hausse de ...
(Date:2/24/2017)... 23, 2017  This report analyzes the worldwide markets ... Products: Intermediates, Analytical, and Others. The ... Pharmaceuticals, and Agrochemicals. The report provides separate comprehensive analytics ... Europe , and Rest of World. Annual ... through 2022. Also, a six-year historic analysis is provided ...
(Date:2/24/2017)... , Feb. 23, 2017  The particle counters ... by 2021 from USD 275.9 million in 2016, ... the full report: http://www.reportlinker.com/p04718602-summary/view-report.html ... on pharmaceutical R&D, and growth in manufacturing industries ... market growth for particle counters. On the other ...
Breaking Medicine Technology:
(Date:2/24/2017)... ... February 24, 2017 , ... In the Health Care IT campaign, Robert ... because it’s not if you will be attacked, but when.” However, he and many ... digital health care. , Improvements in auditing and monitoring have taken security in health ...
(Date:2/24/2017)... Viejo, CA (PRWEB) , ... February 24, 2017 , ... ... Final Cut Pro X . Users have total control over position, rotation, distortion, ... and more all within Final Cut Pro X. , With ProGlass Prism users are ...
(Date:2/24/2017)... ... February 24, 2017 , ... Indiana Fiber Network (IFN) President and ... this year. Dyer started as the Chairman of the Management Committee when IFN ... the corporation including the recruitment of investor/owners and development of the business plan. ...
(Date:2/24/2017)... ... February 24, 2017 , ... Castle ... hosted their Military Wedding Giveaway, with the winning couple announced on Feb. 14, ... services generously donated from local vendors: A Matter of Taste, Ryan Rousseau Enterprises, ...
(Date:2/23/2017)... Miami, FL (PRWEB) , ... February 23, 2017 ... ... largest non-profit organization devoted exclusively to funding innovative lymphoma research and serving the ... services – will return to the La Gorce Country Club in Miami Beach ...
Breaking Medicine News(10 mins):